BioCaptiva

BioCaptiva develops liquid biopsy technology for cancer detection and monitoring, pioneering a proprietary polymer technology called msX for direct capture of cell-free DNA (cfDNA) from biological fluids. The company's patented msX polymers capture cfDNA directly from plasma, whole blood, urine, and pleural effusion without additional reagents, delivering enhanced cfDNA yields with exceptional sample stability for up to 90 days at room temperature and minimal pre-analytical processing. The technology selectively targets low molecular weight DNA, improving signal-to-noise ratios by minimizing high molecular weight and cellular DNA contamination, which enables expanded testing menus, deeper sequencing, and even PCR-free workflows. msX polymers can be coated onto diverse substrates including beads, foams, and solid surfaces, and their ability to capture cfDNA without binding reagents allows sample collection from virtually limitless volumes in flow-through applications. BioCaptiva's product portfolio includes the msX-B and msX-B EAP systems, manufactured under ISO 13485 compliant quality management. The technology overcomes key limitations of current liquid biopsy techniques including restricted sample volumes and poor sample quality, enhancing non-invasive cancer diagnosis, monitoring, and personalized treatment planning. Founded in 2018 and headquartered in Edinburgh, United Kingdom, BioCaptiva has raised $6.2M in seed funding from investors including Archangels, Scottish Enterprise, Cancer Research Horizons, Old College Capital, and BBI Capital.